Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
Terrier J, Gaspar F, Gosselin P, Raboud O, Lenoir C, Rollason V, Csajka C, Samer C, Fontana P, Daali Y, Reny JL; OptimAT study group. Terrier J, et al. Among authors: csajka c. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1872-1883. doi: 10.1002/psp4.13036. Epub 2023 Oct 4. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37794718 Free PMC article.
Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anticancer Therapies Study.
Ravix A, Bandiera C, Cardoso E, Lata-Pedreira A, Chtioui H, Decosterd LA, Wagner AD, Schneider MP, Csajka C, Guidi M. Ravix A, et al. Among authors: csajka c. Cancers (Basel). 2024 Jun 11;16(12):2193. doi: 10.3390/cancers16122193. Cancers (Basel). 2024. PMID: 38927898 Free PMC article.
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C, Cardoso E, Locatelli I, Zaman K, Diciolla A, Digklia A, Stravodimou A, Cristina V, Aedo-Lopez V, Dolcan A, Sarivalasis A, Bouchaab H, Pasquier J, Dotta-Celio J, Peters S, Wagner D, Csajka C, Schneider MP. Bandiera C, et al. Among authors: csajka c. PLoS One. 2024 Jun 7;19(6):e0304573. doi: 10.1371/journal.pone.0304573. eCollection 2024. PLoS One. 2024. PMID: 38848380 Free PMC article. Clinical Trial.
Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project.
Monfort A, Cardoso E, Eap CB, Fischer Fumeaux CJ, Graz MB, Morisod Harari M, Weisskopf E, Gandia P, Allegaert K, Nordeng H, Hascoët JM, Claris O, Epiney M, Csajka C, Guidi M, Ferreira E, Panchaud A. Monfort A, et al. Among authors: csajka c. Front Psychiatry. 2023 May 18;14:1167870. doi: 10.3389/fpsyt.2023.1167870. eCollection 2023. Front Psychiatry. 2023. PMID: 37275991 Free PMC article.
Automatic Detection of Adverse Drug Events in Geriatric Care: Study Proposal.
Gaspar F, Lutters M, Beeler PE, Lang PO, Burnand B, Rinaldi F, Lovis C, Csajka C, Le Pogam MA; SwissMADE study. Gaspar F, et al. Among authors: csajka c. JMIR Res Protoc. 2022 Nov 15;11(11):e40456. doi: 10.2196/40456. JMIR Res Protoc. 2022. PMID: 36378522 Free PMC article.
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P, Abler D, Guidi M, Girard P, Amato F, Vietti Violi N, Dietz M, Guignard N, Wicky A, Latifyan S, De Micheli R, Jreige M, Dromain C, Csajka C, Prior JO, Venkatakrishnan K, Michielin O, Cuendet MA, Terranova N. Courlet P, et al. Among authors: csajka c. CPT Pharmacometrics Syst Pharmacol. 2023 Aug;12(8):1170-1181. doi: 10.1002/psp4.12983. Epub 2023 Jun 16. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37328961 Free PMC article.
165 results